PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/757,077 TRANSMITTAL January 14, 2004 Filing Date **FORM** First Named Inventor Lance E. Steward (to be used for all correspondence after initial filing) Art Unit Not Yet Assigned Not Yet Assigned **Examiner Name** Total Number of Pages in This Submission Attorney Docket Number ALLE0014-103 (17355 CIP3) ENCLOSURES (check all that apply) After Allowance Communication to Fee Transmittal Form ☐ Drawing(s) Group Appeal Communication to Board of Licensing-related Papers ☐ Fee Attached Appeals and Interferences Petition Appeal Communication to Group Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final **Provisional Application** Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Terminal Disclaimer Other Enclosure(s) Extension of Time Request (please identify below): References B1-B3 Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Certified Copy of Priority Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm David A. Sadewasser/Reg. No. 55,587 Individual name Signature Date

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name

David A. Sadewasser

Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Lance E. Steward, et al

Serial No.: 10/757,077 Group Art Unit: Not Yet Assigned

Filing Date: January 14, 2004 Examiner: Not Yet Assigned

For: CLOSTRIDIAL NEUROTOXIN COMPOSITIONS AND MODIFIED CLOSTRIDIAL NEUROTOXINS

DATE OF DEPOSIT: UNIT 15, 2004
I HEREBY CERTIFY THAT THIS PAPER'S BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON
THE DATE INDICATED ABOVE AND IS ADDRESSED TO
THE COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VA 22313-1450

TYPED NAME: David A. Sadewasser REGISTRATION NO:55,587

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This I	niorma	tion Disclosure Statement is being filed:		
	within	three months of the filing date of the patent application.		
		three months of the date of entry into the national stage as set forth in R. § 1.491 of the international application.		
\boxtimes	before	the mailing date of a first Office Action on the merits.		
	mailin	the mailing date of a first Office Action on the merits, but before the g date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of ance under 37 C.F.R. § 1.311, and accordingly is accompanied by:		
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);		
		or		
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or		
	\boxtimes	No fee is owed by the applicant(s).		
	Statem Final S C.F.R.	cordance with 37 C.F.R. § 1.129(a), this Information Disclosure nent is being filed in connection with the first or second After Submission, and accordingly is accompanied by the Statement under 37 § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in F.R. § 1.17(p), is attached.		
	Notice with, t Statem Inform	the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously the payment of the Issue Fee, and accordingly is accompanied by the nent under 37 C.F.R. § 1.97(e), a Petition requesting consideration of the nation Disclosure Statement and the Petition Fee of \$130.00 set forth in F.R. § 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).		
×		s of references (B1-B3) listed on the attached PTO Form SB/08A and form SB/08B, formerly known as PTO Form 1449 are enclosed.		
	EXCEPT THAT:			
		In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.		
		In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.		

·		Copies of references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 were previously cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No. @@ filed on If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
Stater	nent un	nder 37 C.F.R. § 1.97(e)
	in the foreign	ndersigned attorney hereby states that each item information contained Information Disclosure Statement was cited in a communication from a n patent office in a counterpart foreign patent application not more than months prior to the filing of the Information Disclosure Statement.
Stater	nent un	der 37 C.F.R. § 1.704(d)
	contain comm the con in §1.5	ndersigned attorney hereby states that each item of information ned in the Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart application and mmunication was not received by any individual designated 56(c) more than 30 days prior to the filing of the Information osure Statement.
Fees		
\boxtimes	No Fe	e is owed by the applicant(s).
		nformation Disclosure Statement Fee of \$180.00 under 37 C.F.R. (p) is enclosed herewith.
	The Po	etition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.
Metho	od of Pa	ayment of Fees
		ned is a check in the amount of \$ This form is tted in duplicate.
		e Deposit Account No. 50-1275 in the amount of \$180.00. This form is tted in duplicate.
\boxtimes	Please	charge any deficiency or credit any overpayment to Deposit Account 75.

 \boxtimes No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,

Dated: July 15, 2004

COZEN O'CONNOR, P.C.

1900 Market Street, 5th Floor Philadelphia, PA 19103-3508 (215) 665-2000 – Telephone (215) 665-2013 - Facsimile

David A. Sadewasser

Registration No. 55,587

PTO/SB/08b(08-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known Application Number 10/757,077 INFORMATION DISCLOSURE January 14, 2004 Filing Date STATEMENT BY APPLICANT Lance E. Steward First Named Inventor Art Unit Not Yet Assigned (Use as many sheets as necessary) Examiner Name Not Yet Assigned Sheet of Attomey Docket Number ALLE0014-103 (17355 CIP3)

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²			
	B1	FERNANDEZ-SALAS, et al., "Plasma Membrane Localization Signals in the Light Chain of Botulinum Neurotoxin," Slide presentation at USAMRDD, January, 2004.				
	B2	FERNANDEZ-SALAS, et al., "Plasma membrane localization signals in the light chain of botulinum neurotoxin," Proc. Natl. Acad. Sci. USA (2004) 101:3208-3213.				
	ВЗ	FERNANDEZ-SALAS, et al., "Is the light chain subcellular localization an important factor in Botulinum toxin duration of action?" Movement Disorders (2004) 19:S23-S34.				
_						

Considered Signature

Examiner

Date

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suppositions for reducing this burden, about the this Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.